GHK-Cu

Description of GHK-Cu

The human copper-binding peptide GHK-Cu (glycyl-l-histidyl-l-lysine) is a naturally occurring tri-peptide found in human plasma and released from tissues during injury. Discovered in 1973, GHK-Cu has established itself as a powerful protective and regenerative ingredient, widely used in skin and hair products. GHK-Cu tightens loose skin, repairs protective skin barrier proteins, and improves skin firmness, elasticity, and clarity. It reduces fine lines, wrinkles, and photodamage, and smooths rough skin. Additionally, GHK-Cu stimulates wound healing, protects skin cells from UV radiation, reduces inflammation and free radical damage, and enhances hair growth and thickness. Its effects are largely attributed to its ability to bind copper(II) ions, playing a crucial role in copper metabolism. Recent research, utilizing the Connectivity Map from the Broad Institute, has shown that GHK-Cu can up- and down-regulate numerous human genes, linking its biological effects to changes in gene expression.

Further research on GHK-Cu reveals its presence in human blood plasma, urine, and saliva. Animal studies indicate that GHK-Cu can significantly enhance wound healing, immune function, and skin health by stimulating collagen production, promoting blood vessel growth, and supporting fibroblast activity.

Now we would like to bring you closer to the effects of the peptide, which have been researched and confirmed in studies.

Research Confirmed Effects

1. GHK-Cu and Skin Healing

GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring peptide in human plasma, saliva, and urine that declines with age. Known for its powerful protective and regenerative properties, GHK-Cu accelerates wound healing and skin repair by stimulating the synthesis and breakdown of collagen, glycosaminoglycans, and other extracellular matrix components. It modulates the activity of metalloproteinases and their inhibitors, promoting the healing of various tissues such as skin, hair follicles, and bones. In cosmetic products, GHK-Cu is effective in tightening loose skin, improving elasticity and firmness, reducing fine lines, wrinkles, and hyperpigmentation, and enhancing overall skin appearance. Additionally, it has therapeutic potential for conditions like skin inflammation, chronic obstructive pulmonary disease, and metastatic colon cancer, owing to its ability to regulate thousands of human genes, essentially resetting DNA to a healthier state.

Recent studies have highlighted GHK-Cu's role in modulating key growth factors involved in wound healing and skin regeneration. Transforming growth factor β (TGF-β) and insulin growth factor (IGF) are crucial in these processes, with GHK-Cu shown to decrease IGF-2-dependent TGF-β1 secretion in dermal fibroblasts, potentially preventing hypertrophic scar formation. Furthermore, GHK-Cu encapsulated in liposomes has been demonstrated to accelerate scald wound healing in mice by promoting cell proliferation and angiogenesis, enhancing the expression of vascular endothelial growth factor and fibroblast growth factors, and improving the overall healing process. These findings underscore the peptide's potential as a powerful therapeutic agent in skin regeneration and wound healing applications.

2. GHK-Cu and Bacteria

In vitro studies have highlighted the promising antimicrobial activity of Gly-His-Lys conjugates for potential therapeutic use in skin and tissue infections. These studies explored novel compounds, including fatty acid conjugates with modified Gly-His-Lys sequences. The antimicrobial efficacy of these compounds ranged from strong to moderate. Notably, compound 1d exhibited the most potent activity against Escherichia coli and Staphylococcus aureus with MIC ranges of 31.3–125.0 μg/mL and against Pseudomonas aeruginosa with MIC ranges of 375.0–500.0 μg/mL. Conjugate 5b showed significant activity against Staphylococcus aureus and Escherichia coli at MIC ranges of 250.0–500.0 μg/mL and 62.5–125.0 μg/mL, respectively. Both 1d and 5b demonstrated rapid bactericidal effects against Gram-positive bacteria. Additionally, compounds 1d, 1e, and 2e showed notable antifungal activity.

A multicenter, randomized, evaluator-blinded, placebo-controlled clinical study evaluated the effectiveness of the glycyl-L-histidyl-L-lysine copper complex (lamin Gel) in treating diabetic neuropathic ulcers. Patients adhered to a standardized wound care protocol, including sharp debridement, daily drug application, pressure-relieving footwear, and diabetes management education. Treatment with lamin Gel significantly improved ulcer closure rates, achieving a median area closure of 98.5% compared to 60.8% for the control group. The rate of closure was three times faster with lamin Gel, particularly for larger ulcers (greater than 100 mm²), which showed an 89.2% closure compared to -10.3% for the control. Immediate treatment post-debridement was crucial for optimal results. Additionally, the incidence of ulcer infections was significantly lower in the lamin Gel group (7%) compared to the control (34%).

An experimental study on the effects of topical glycyl-L-histidyl-L-lysine tripeptide-copper complex (TCC) on ischemic open wounds in rats further supported the benefits of GHK-Cu. Rats treated with TCC showed a significant decrease in wound area compared to control and vehicle groups. By day 13, the TCC group exhibited a 64.5% reduction in wound area, outperforming the vehicle (45.6%) and control (28.2%) groups. TCC-treated wounds also had significantly lower concentrations of TNF-alpha and MMP-2 and MMP-9, indicating reduced inflammation and enhanced healing. These findings suggest that TCC could be an effective treatment for chronic wounds in various species, including humans.

Overall, GHK-Cu has shown superior results in treating diabetic ulcers and ischemic open wounds compared to standard care alone. Its combination with certain fatty acids creates a potent antimicrobial compound effective against bacteria and fungi, potentially reducing infection rates and accelerating wound healing. These findings warrant further clinical evaluation of GHK-Cu for broader therapeutic applications in wound care.

3. GHK-Cu in Cognition and Nervous System

Neurodegeneration, characterized by the progressive death of neurons and cognitive decline, is a growing concern among senior populations, with limited effective therapies available. One potential therapeutic agent is the human peptide GHK (glycyl-L-histidyl-L-lysine), a copper-binding peptide known for its diverse biological actions that counteract aging-related diseases and conditions. GHK has shown health-promoting effects on various tissues, including chondrocytes, liver cells, and human fibroblasts. Importantly, studies using the Broad Institute Connectivity Map have demonstrated that GHK can modulate gene expression, resetting pathological patterns to healthier states.

In research focused on the nervous system, GHK has demonstrated neuroprotective effects against neurodegenerative diseases and improved tissue regeneration. A study on rats with intracerebral hemorrhage (ICH) revealed that GHK pretreatment significantly improved neurological deficits, reduced brain water content, and inhibited neuronal apoptosis. The peptide's effects were mediated through the downregulation of miR-339-5p expression, which was found to be part of the p38 MAPK pathway. Additionally, GHK's influence on the miR-339-5p/VEGFA axis played a crucial role in preventing neuronal apoptosis following ICH injury. These findings suggest that GHK could represent a novel therapeutic strategy for conditions like ICH.

GHK-Cu, a variant of the peptide found in high concentrations in the brain, has been studied for its ability to counteract age-associated decline in neuron function. Research indicates that GHK-Cu improves angiogenesis in the nervous system, enhances nerve outgrowth, and reduces central nervous system inflammation. It appears to reset pathological gene expression, helping to restore health in dysfunctional systems. In rat models, GHK-Cu's neuroprotective effects were evident through improved neurological deficits, reduced brain swelling, and inhibition of neuron death. These effects were particularly notable in the context of overexpression of miR-339-5p following brain injuries such as bleeds and strokes, underscoring GHK-Cu's potential as a protective agent against neurodegeneration.

4. GHK-Cu and Side Effects of Chemotherapy

GHK peptide shows promise in inhibiting bleomycin-induced pulmonary fibrosis in mice by suppressing the TGF-β1/Smad-mediated epithelial-to-mesenchymal transition (EMT). Pulmonary fibrosis, an irreversible and progressive lung disease, lacks effective treatments. It occurs after therapy with bleomycin – cancer drug. GHK, a tripeptide known for its role in tissue regeneration and wound healing, was tested for its effects on bleomycin-induced fibrosis. Mice were administered GHK intraperitoneally at various doses following bleomycin instillation. Results demonstrated that GHK treatment reduced inflammatory cell infiltration, improved collagen deposition, and balanced MMP-9/TIMP-1 levels. It also decreased TNF-α, IL-6 in bronchoalveolar lavage fluid, and myeloperoxidase activity in lung extracts. GHK further inhibited TGF-β1, p-Smad2, p-Smad3, and IGF-1 expression, indicating its potential as a treatment for pulmonary fibrosis by targeting the TGF-β1/Smad 2/3 and IGF-1 pathways.

GHK-Cu, the copper-bound form of the peptide, also exhibits protective effects against lipopolysaccharide (LPS)-induced acute lung injury (ALI) in mice. GHK-Cu treatment reduced reactive oxygen species (ROS) production, increased superoxide dismutase (SOD) activity, and decreased TNF-α and IL-6 production by inhibiting NF-κB p65 and p38 MAPK signaling in LPS-induced macrophages and ALI models. This treatment alleviated lung histological alterations and suppressed inflammatory cell infiltration, demonstrating GHK-Cu's potential as a novel therapeutic approach for ALI and acute respiratory distress syndrome (ARDS) by mitigating excessive inflammatory responses.

Research highlights the efficacy of GHK-Cu in protecting lungs from fibrosis following bleomycin therapy, suggesting its use as a chemotherapy adjuvant to increase medication doses without exacerbating side effects. GHK-Cu regulates inflammatory molecules TNF-α and IL-6, preventing fibrotic remodeling and improving collagen deposition in the lungs. Similarly, GHK-Cu showed benefits in mouse models of ARDS, reducing TNF-α and IL-6 expression, and offering a protective effect against this rapid and potentially fatal inflammatory lung condition. These findings support GHK-Cu's potential therapeutic application in treating various lung injuries and diseases.

5. GHK-Cu and Pain Reduction

GHK-Cu exhibits promising analgesic and anti-aggressive effects in rat models, particularly in response to pain-induced aggressive-defensive behavior. Administered intraperitoneally in doses ranging from 5 to 150 μg/kg, GHK-Cu demonstrated significant pain relief and reduction in aggressive behavior in a foot-shock model. The key to these effects lies in the L-lysine residue within the GHK peptide, as similar analgesic and anti-aggressive effects were observed with L-lysine administration at equivalent doses.

Furthermore, the peptide's efficacy extends to interactions with L-arginine, another amino acid with analgesic properties. Research has shown that combining arginine with glyprolines to form specific peptides can produce intrinsic regulatory effects on pain and aggression. This suggests that GHK-Cu and related peptides could be developed as non-addictive alternatives to opiate medications and NSAIDs, which are known for their potential side effects, including negative impacts on cardiovascular health. These findings highlight the therapeutic potential of GHK-Cu in pain management, offering a new avenue for developing safer pain relief options.

📚 Academic References & Citations

3rd party test results